Navigation Links
Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
Date:7/1/2008

he highest concentration in milk, is expressed throughout the body in immune cells and on all body surfaces exposed to the external environment. Lactoferrin plays an important role in helping to establish the immune system, including the Gut Associated Lymphoid Tissue (GALT), in infants. Talactoferrin is produced in Aspergillus niger, a filamentous fungus, and is structurally identical to native human lactoferrin in all material respects, differing only in its glycosylation.

Talactoferrin is an orally administered protein that mediates its activity through the gut and the GALT -- the largest lymphoid organ in the body. It acts through a novel mechanism of dendritic cell recruitment and activation. Following oral administration, talactoferrin is transported by the M-cells into the small intestinal Peyer's Patches, where it recruits circulating immature dendritic cells bearing tumor antigens to the GALT and induces their maturation. DC maturation in the presence of tumor antigens and lymphoid effector cells induces a strong systemic innate and adaptive immune response mediated by anti-cancer Natural Killer (NK) cells, CD8+ lymphocytes and NK-T cells. This results in the activation of tumor-draining lymph nodes, cellular infiltration of distant tumors and tumor-cell death. Mounting the initial immune response in the GALT -- away from the primary tumor and using a physiologically important pathway -- minimizes the effect of the cancer's local immunosuppressive defenses.

About Renal Cell Carcinoma (RCC) RCC is the most common type of kidney cancer, accounting for approximately 90 percent of kidney tumors. In the United States, RCC affects over 40,000 patients per year, and is responsible for close to 13,000 deaths. Kidney cancer is uncommon under age 45, and its incidence is highest between the ages of 55 and 84.

Once RCC is metastatic, it is difficult to treat, and median survival is between one and two years. A number of different modalities are av
'/>"/>

SOURCE Agennix Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Mid-Term Results on CryoValve(R) SG Pulmonary Human Heart Valve Presented at Western Thoracic Meeting
2. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
3. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
4. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
5. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
6. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
7. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
8. Inspires Phase 3 CF Trial, Using PARIs Nebulizer & Compressor, Shows Positive Top-Line Results
9. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
10. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
11. Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today announced ... platform during a special event at the company,s office ... on September 5, 2014. The event, which will start ... ApolloDx website, www.apollodx.com .    "We ... said Jared Bauer , Co-Founder and Managing Partner ...
(Date:8/20/2014)... DIEGO , Aug. 20, 2014 Trovagene, ... diagnostics, announced today that results from two clinical studies ... conference for the Company,s urine-based diagnostic test for the ... The IPV conference is scheduled to take place in ... to 25 th . Additionally, a new U.S. ...
(Date:8/20/2014)... Phase I Trial of Plasma ... KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with a ... it has begun a Phase I, First in Human, ... the treatment of DME. The study,s Principal Investigator is ... Joslin Diabetes Center; Harvard Medical School Department of Ophthalmology, ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... conjunction with DURECT Corporation,s (Nasdaq: DRRX ) fourth ... listen to the conference call that will be broadcast live ... pm Eastern Time (1:30 pm Pacific Time). (Logo: ... the presentation will be available by accessing DURECT,s homepage at ...
... -- The SimplyGo Portable Oxygen Concentrator by Philips ... continuous flow and pulse does at a weight of only ... lightest weight continuous flow portable concentrator weighed in at a ... voltage meaning anywhere you go in the world you can ...
Cached Medicine Technology:SimplyGo Portable Oxygen Concentrator Now Available 2
(Date:8/21/2014)... 2014 The employees of Pharmica ... Washington Crossing, Pennsylvania on Thursday, August 7th to spend ... been looking for different ways that Pharmica could get ... with Pharmica Consulting. “When we heard that we could ... we jumped at the opportunity.” , Pharmica spent their ...
(Date:8/21/2014)... 21, 2014 Sometimes you have to lose the ... new book “From Zero to a Hundred: Finding My Purpose through ... story of surviving a broken family, a childhood of gang violence ... who you were created to be,” Roy said. “I didn’t give ... I know my purpose today of helping others overcome their trials.” ...
(Date:8/21/2014)... Michael E. Steuer , local doctor in ... the Bluff City with recent philanthropy at local synagogue. “The ... United States,” says friend and Rabbi David Julian of Or ... as providing in-house for the needy and teaching Hebrew to ... the local synagogue. And to remain close with the development ...
(Date:8/21/2014)... Drake University’s Phi Gamma Delta (FIJI) and ... cancer research, according to Billy Cundiff, President of Colleen’s ... for the Cleveland Browns, says the money raised by ... Dream Foundation and will fund research to be conducted ... Division of Gynecologic Oncology at the University of Iowa’s ...
(Date:8/21/2014)... Recently, BambooIndustry.com, one of the most famous ... new range of hand scraped bamboo floorings ... an Autumn special offer for these elegant items. According ... a discounted price, up to 25% off; the promotion ... , Providing natural looks and available in different varieties, ...
Breaking Medicine News(10 mins):Health News:Pharmica Spends the Day Helping to Preserve Washington Crossing Historic Park 2Health News:Zero to a Hundred: True Story of Escaping Death to Meet Life 2Health News:Drake University’s Phi Gamma Delta (FIJI) and Colleen’s Dream Foundation Donate $10,000 to the University of Iowa’s Holden Cancer Center to Fight Ovarian Cancer 2Health News:Drake University’s Phi Gamma Delta (FIJI) and Colleen’s Dream Foundation Donate $10,000 to the University of Iowa’s Holden Cancer Center to Fight Ovarian Cancer 3Health News:Cheap Hand Scraped Bamboo Floorings Recently Unveiled by BambooIndustry.com 2
... Anderson Hospital administration and their ED process improvement ... the ED Patient Throughput Team at ... The ED Patient Throughput Team, responsible for reducing wait times ... three finalists to receive the award for their excellence in ...
... higher in moms-to-be who snore, study finds , THURSDAY, June ... more likely to develop gestational diabetes, new research has found. ... survey when they were between six and 20 weeks pregnant, ... that pregnant women who were frequent snorers -- defined as ...
... ... him uniquely qualified to lead NVCI , ... Las Vegas, NV (PRWEB) June 11, 2009 -- Stephen J. ... as Chairman of the Board for the Nevada Cancer Institute (NVCI) effective July 1, ...
... As a result of the economic climate, high-technology and ... in addition to extending cost controls for their current ... Aon Consulting,s Radford, a leading provider of compensation intelligence ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20041215/CGW049LOGO ) , ...
... had best results in study , THURSDAY, June 11 (HealthDay ... diabetes, may also help non-diabetic obese people lose weight when ... Researchers divided 152 obese men and women (with a body-mass ... 241 pounds) into two groups. About 25 percent of the ...
... Researchers at Nationwide Children,s Hospital and Johns Hopkins University ... highly expressed in normal tissues but lost in diseased ... (miRNA) are a class of small RNA molecules that ... in gene expression and in maintaining normal cell development ...
Cached Medicine News:Health News:Anderson ED Team Receives Pinnacle Award for Excellence in Customer Service 2Health News:Anderson ED Team Receives Pinnacle Award for Excellence in Customer Service 3Health News:Frequent Snoring in Pregnancy Could Signal Blood Sugar Trouble 2Health News:Nevada Cancer Institute Names Stephen J. Cloobeck Chairman of the Board 2Health News:Nevada Cancer Institute Names Stephen J. Cloobeck Chairman of the Board 3Health News:Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate, Says Aon Consulting's Radford 2Health News:Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate, Says Aon Consulting's Radford 3Health News:Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate, Says Aon Consulting's Radford 4Health News:Diabetes Drug Byetta May Aid Weight Loss in Obese Patients 2Health News:Study shows promise for new cancer-stopping therapy 2
... easy-to-use 3800 and 3900/P pulse oximeters ... the proprietary clinical patient motion algorithm ... improved performance:, ,The 3800 and ... rigorous environmental/ mechanical stress testing such ...
... The Acuity LT Central Monitoring Station provides ... and ready to go right out of ... surveillance in specific care areas rather than ... ICU. As patient-to-caregiver ratios continue to climb ...
... 3800 and 3900/P pulse oximeters are ... proprietary clinical patient motion algorithm from ... performance:, ,The 3800 and 3900 ... environmental/ mechanical stress testing such as ...
... Researchers., ,S/5 Collect and S/5 Collect4 provides ... collect data from Datex-Ohmeda monitors. Data can be ... intervals. With S/5 Collect you have ability to ... interface cable or connect directly from S/5 Central. ...
Medicine Products: